NCT05027594终止1 期
A Phase I Dose Escalation Study of NMS-03597812, a PERK Inhibitor, in Adult Patients With Relapsed or Refractory Multiple Myeloma
Nerviano Medical Sciences2 个研究点 分布在 1 个国家目标入组 65 人开始时间: 2022年9月9日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 终止
- 发起方
- 入组人数
- 65
- 试验地点
- 2
- 主要终点
- Number of Participants with first-cycle dose limiting toxicity
研究概览
简要总结
This is a Phase I, first-in-human (FIH), open-label, non-randomized, multi-center study to explore the safety, tolerability, pharmacokinetics and preliminary antitumor activity of NMS-03597812 in adult patients with RRMM who have exhausted standard treatment options that are expected to provide meaningful clinical benefit or for whom standard therapy is considered unsuitable.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Sequential
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients must have a confirmed diagnosis of relapsed or relapsed and refractory multiple myeloma (as per IMWG criteria)
- •Patients must have exhausted available therapeutic options that are expected to provide meaningful clinical benefit, either through disease relapse, treatment refractory disease, intolerance or refusal of the therapy.
- •Patients must have received at least three prior lines of therapy as defined by IMWG, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 antibody.
- •Patients must have progressive/refractory disease to the last line of therapy.
- •Patients must have measurable disease, defined as any of the following:serum monoclonal protein ≥ 0.5 g/dL by protein electrophoresis, ≥200 mg of monoclonal protein in urine on 24-h electrophoresis, or serum immunoglobulin free light chain ≥10 mg/dL with abnormal free-light-chain ratio.
- •Adult (age ≥18 years) patients.
- •Karnofsky performance status ≥60%.
- •All acute toxic effects (excluding alopecia) of any prior therapy must have resolved to NCI CTCAE version 5.0 Grade ≤1 or according to inclusion criterion
- •Adequate hematological profile, renal, hepatic and pancreatic functions
- •All female patients with reproductive potential must have a negative pregnancy test (serum or urine) within the screening period prior to start of the study drug.
- •Patients must use effective contraception or abstinence. Female patients of childbearing potential must agree to use effective contraception or abstinence during the period of therapy and in the following 90 days after discontinuation of study treatment. Male patients must be surgically sterile or must agree to use effective contraception or abstinence during the period of therapy and in the following 90 days after discontinuation of study treatment.
- •Ability to swallow capsules intact (without chewing, crushing, or opening).
- •Willingness and ability to comply with scheduled visits, treatment plan, laboratory tests and other study indications or procedures.
- •Signed and dated IRB/EC-approved Informed Consent
排除标准
- •Current enrollment in another interventional clinical study.
- •Diagnosis of primary refractory multiple myeloma defined as disease that is non-responsive in patients who have never achieved a minimal response or better with any therapy
- •Diagnosis of plasma cell leukemia, Waldenstrom's macroglobulinemia or amyloidosis.
- •Diagnosis of non-secretory myeloma.
- •Known central nervous system (CNS) involvement by multiple myeloma.
- •Known history of polyneuropathy, organomegaly, endocrinopathy, monoclonal protein and skin changes (POEMS) syndrome.
- •Currently active second malignancy, except for adequately treated basal or squamous cell skin cancer and/or conebiopsied in situ carcinoma of the cervix uteri and/or superficial bladder cancer.
- •Autologous stem cell transplant ≤3 months prior to starting NMS-
- •Prior allogeneic hematopoietic stem cell transplant (HSCT) with either standard or reduced intensity conditioning ≤6 months prior to starting NMS-
- •Active acute or chronic graft versus host disease (GVHD) requiring immunosuppressive treatment. Patients who experienced GVHD requiring immunosuppressive treatment, must have stopped immunosuppressive treatment >3 months prior to starting NMS-
- •Any anticancer agent within 3 weeks (6 weeks for immunotherapy or nitrosoureas).
- •Prior CAR-T cell <3 months prior to starting NMS-
- •Concomitant oral prednisone(or equivalent)>10 mg/day. Doses of corticosteroid must have been stable for at least 7 days before startingNMS-
- •Major surgery within 4 weeks before treatment start.
- •Radiotherapy within 3 weeks prior to starting NMS-
- •However, if the radiation portal covered ≤ 5% of the bone marrow reserve, the patient may be enrolled irrespective of the end date of radiotherapy.
- •Patient with evidence of clinically significant mucosal or internal bleeding.
- •Patient platelet transfusion refractory.
- •History of pancreatitis or current alcohol abuse.
- •Uncontrolled diabetes.
- •Patients with QTc interval ≥ 480 milliseconds or with risk factors for torsade de pointes (e.g., uncontrolled heart failure, uncontrolled hypokalemia, history of prolonged QTc interval or family history of long QT syndrome). For patients receiving treatment with concomitant medications known to prolong the QTc interval, replacement with another treatment should be considered. If replacement or discontinuation is not clinically feasible, a careful risk/benefit evaluation should be performed prior to enrollment.
- •Breast-feeding or planning to breast feed during the study or within 3 months after study treatment.
- •Known hypersensitivity to any of the components of the NMS-03597812 drug product.
- •Known hypersensitivity to steroids or any of the components of the dexamethasone drug product (applies only to the expansion cohort testing NMS-03597812 in combination with dexamethasone).
- •Any of the following in the previous 6 months: myocardial infarction, unstable angina, coronary/peripheral artery bypass graft, NYHA class III or IV congestive heart failure, cerebrovascular accident or transient ischemic attack, or pulmonary embolism.
- •Uncontrolled bacterial, viral, or fungal infections including: known infection with HIV, HBV and/or HCV; patients who are seropositive following HBV vaccine are eligible.
- •Known active gastrointestinal disease (e.g., documented gastrointestinal ulcer, Crohn's disease, ulcerative colitis or short gut syndrome) or other malabsorption syndromes that would impact drug absorption or represent a contra-indication for the treatment with dexamethasone (NMS-03597812 and dexamethasone expansion cohort).
- •Other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or study drug administration or may interfere with the interpretation of study results and, in the judgment of the Investigator, would make the patient inappropriate for entry into this study or could compromise protocol objectives in the opinion of the Investigator and/or the Sponsor.
- •Patient who are receiving concomitant medications that are strong inducers or inhibitors of CYP34A and CYP2C9 that cannot be replaced with alternative therapy.
- •Patients who are receiving concomitant medications that are sensitive substrates of CYP3A4 and CYP2D6 with narrow therapeutic window that cannot be replaced with alternative therapy.
研究组 & 干预措施
Dose Escalation Part
Experimental
Patients with a confirmed diagnosis of relapsed or relapsed and refractory multiple myeloma (as per IMWG criteria) who have exhausted standard treatment options that are expected to provide meaningful clinical benefit or for whom standard therapy is considered unsuitable
干预措施: NMS-03597812 (Drug)
Dose Expansion Part - NMS-03597812 single agent
Experimental
Patients with a confirmed diagnosis of relapsed or relapsed and refractory multiple myeloma (as per IMWG criteria) who have exhausted standard treatment options that are expected to provide meaningful clinical benefit or for whom standard therapy is considered unsuitable
干预措施: NMS-03597812 (Drug)
Dose Expansion Part - NMS-03597812 in combination with dexamethasone
Experimental
Patients with a confirmed diagnosis of relapsed or relapsed and refractory multiple myeloma (as per IMWG criteria) who have exhausted standard treatment options that are expected to provide meaningful clinical benefit or for whom standard therapy is considered unsuitable
干预措施: NMS-03597812 + dexamethasone (Drug)
结局指标
主要结局
Number of Participants with first-cycle dose limiting toxicity
时间窗: Time interval between the date of the first dose administration in Cycle 1 (each cycle is 28 days) and the date of the first dose administration in Cycle 2 which is expected to be 28 days or up to 42 days in case of dose delay due to toxicity
For DLT evaluation, severity (grade) is classified according to common terminology criteria for adverse events version 5.0 (CTCAE v5.0).
次要结局
- Number of Participants with Overall Response(From treatment start date until disease progression or relapse (up to approximately 12 months).)
- Time to maximum plasma concentration (Tmax) of NMS-03597812 after single and multiple doses of drug(At Cycle 1 (each cycle is 28 days) on Days 1, 2, 8, 15, 21, 22, 23 and 24 and at Cycle 2 on Days 1, 8, 15, 21, at different timepoints.)
- Oral plasma clearance (CL/F) of NMS-03597812 after multiple doses of drug(At Cycle 1 (each cycle is 28 days) on Days 1, 2, 8, 15, 21, 22, 23 and 24 and at Cycle 2 on Days 1, 8, 15, 21, at different timepoints.)
- Average plasma concentration (Cave) of NMS-03597812 after multiple doses of drug(At Cycle 1 (each cycle is 28 days) on Days 1, 2, 8, 15, 21, 22, 23 and 24 and at Cycle 2 on Days 1, 8, 15, 21, at different timepoints.)
- Terminal elimination half-life (t1/2) of NMS-03597812 after multiple doses of drug(At Cycle 1 (each cycle is 28 days) on Days 1, 2, 8, 15, 21, 22, 23 and 24 and Cycle 2 on Days 1, 8, 15, 21, at different timepoints)
- Progression Free Survival (PFS)(From date of first dose of study drug up to the date of first documentation of disease progression/relapse or death due to any cause, whichever comes first (up to approximately 12 months).)
- Accumulation ratio (Rac) of NMS-03597812 after multiple doses of drug(At Cycle 1 (each cycle is 28 days) on Days 1, 2, 8, 15, 21, 22, 23 and 24 and at Cycle 2 on Days 1, 8, 15, 21, at different timepoints)
- Cumulative amount recovered unchanged in the urine expressed as a fraction of administered dose (Ae%) of NMS-03597812 after multiple doses of drug.(At Cycle 1 (each cycle is 28 days) Day 1 and Day 21)
- Number of participants with Adverse Events (AEs)(From the Informed Consent signature to 28 days after the last dose of study treatment administration)
- Area under the plasma concentration versus time curve to infinity (AUCinf) of NMS-03597812 after multiple doses of drug(At Cycle 1 (each cycle is 28 days) on Days 1, 2, 8, 15, 21, 22, 23 and 24 and Cycle 2 on Days 1, 8, 15, 21 at different timepoints.)
- Apparent volume of distribution (Vd/F) of NMS-03597812 after multiple doses of drug(At Cycle 1 (each cycle is 28 days) on Days 1, 2, 8, 15, 21, 22, 23 and 24 and at Cycle 2 on Days 1, 8, 15, 21, at different timepoints)
- Cumulative amount recovered unchanged in the urine (Ae) of NMS-03597812 after multiple doses of drug(At Cycle 1 (each cycle is 28 days) Day 1 and Day 21)
- Number of Participants by Best Tumor response(From treatment start date until disease progression or relapse (up to approximately 12 months).)
- Number of Participants with Clinical Benefit(From treatment start date until disease progression or relapse (up to approximately 12 months).)
- Duration of Response(From the first responding tumor assessment until Progression Disease/Relapse or Death due to Progression (up to approximately 12 months))
- Maximum concentration (Cmax) of NMS-03597812 after single and multiple doses of drug(At Cycle 1 (each cycle is 28 days) on Days 1, 2, 8, 15, 21, 22, 23 and 24 and at Cycle 2 on Days 1, 8, 15, 21 at different timepoints.)
- Area under the plasma concentration versus time curve up to the last detectable plasma concentration (AUClast) of NMS-03597812 after single and multiple doses of drug(At Cycle 1 (each cycle is 28 days) on Days 1, 2, 8, 15, 21, 22, 23 and 24 and at Cycle 2 on Days 1, 8, 15, 21, at different timepoints.)
- Minimum plasma concentration (Cmin) of NMS-03597812 after single and multiple doses of drug.(At Cycle 1 (each cycle is 28 days) on Days 1, 2, 8, 15, 21, 22, 23 and 24 and at Cycle 2 on Days 1, 8, 15, 21, at different timepoints.)
- Renal clearance of NMS-03597812 after multiple doses of drug.(At Cycle 1 (each cycle is 28 days) Day 1 and Day 21)
研究者
研究点 (2)
Loading locations...
相似试验
进行中（未招募）
1 期
Study of NMS-03305293 in Pts With Selected Advanced/Metastatic Solid TumorsAdvanced/Metastatic Solid TumorsNCT04182516Nerviano Medical Sciences150
已完成
1 期
First-in-Man, Dose-escalation Trial of C-met Kinase Inhibitor MSC2156119J in Subjects With Advanced Solid TumorsPatients With Solid Tumors, Either Refractory to Standard Therapy or for Which no Effective Standard Therapy is AvailableNCT01014936EMD Serono149
已完成
1 期
AZD5153 in Patients With Relapsed or Refractory Solid Tumors, Including LymphomasMalignant Solid TumorsBreast CancerProstate CancerOvarian CancerLymphomaPancreatic CancerNCT03205176AstraZeneca49
招募中
1 期
A Phase I/II Study of CS2009 in Participants With Advanced Solid TumorsAdvanced Solid TumorsNCT06741644CStone Pharmaceuticals800
已完成
1 期
A Study to Assess Safety and Pharmacokinetics of MOXR0916 in Participants With Locally Advanced or Metastatic Solid TumorsNeoplasmsNCT02219724Genentech, Inc.174